HOXB13 and pachyonychia congenita: In the currently ongoing trial PSMAddition (NCT04720157), which is comparing 177Lu-PSMA-617 therapy plus the standard of care with the standard of care alone in newly diagnosed metastatic hormone-sensitive PC, secondary analysis of diagnostic prostate biopsy tissue for HOXB13 expression may reveal which patients are better suited for upfront PSMA-targeted radiopharmaceutical therapy.